What Alozof Treats: Main Uses and Benefits

Alozof (Fluconazole) is an antifungal agent commonly used to help with a broad range of infections caused by fungi and yeasts, addressing symptoms across several critical therapeutic domains. This medicine is applied in addressing conditions like candidemia, cryptococcal meningitis, and infections of the mucous membranes, including oral thrush, esophageal candidiasis, and recurrent vaginal candidiasis.

Symptomatic Relief and Stability

This medication is used for managing symptom clusters related to systemic imbalance, inflammation, and localized pain, which often interfere with daily functioning and create noticeable physiological strain. The core benefit is that it supports patients during difficult episodes by targeting the causative organism, which contributes to easing the overall symptom load.

“The primary goal is providing support that helps ease the overall symptom burden and assists with maintaining functional stability.”

Alozof is also relevant for prophylaxis—preventive use in high-risk, immunocompromised patients—where its application may assist with reducing the incidence and supporting the management of recurrent serious fungal disease. It helps improve day-to-day comfort during symptomatic periods and is applied across domains where additional symptomatic support is needed.

---

Quick Fact: Relief for Severe Fungal Symptoms Alozof is commonly used to help manage severe systemic infections where symptoms are related to internal fungal invasion of critical organs like the blood or central nervous system.

Regulatory References

1. NIH MedlinePlus Drug Information

Alozof (Fluconazole) eligibility is officially defined by patient age, organ function, reproductive status, and specific pre-existing conditions, as outlined in regulatory documentation.

Absolute Contraindications (Prohibited Use)

Alozof is contraindicated and must not be used in patients with known hypersensitivity to fluconazole or any of its components [1.1]. It is also prohibited for patients receiving co-administration with drugs known to prolong the QT interval and metabolized by the CYP3A4 enzyme, such as cisapride or pimozide [1.1]. Use of certain formulations is contraindicated in patients with hereditary disorders like galactose intolerance or sucrase-isomaltase deficiency [1.5].

Conditional Use and Restrictions

Population	Regulatory Status	Constraint Basis
Renal Impairment	Conditional Use	Dose reduction may be required for multiple-dose therapy due to reduced kidney clearance [1.3].
Hepatic Dysfunction	Use with Caution	Must be administered with caution due to the risk of liver toxicity [1.3].
Heart Conditions	Use with Caution	Caution is advised in patients with heart rhythm problems or electrolyte abnormalities [1.4].

Age and Reproductive Status

• Age: Safety and efficacy are established for adults and most pediatric patients (children ge 6 months) [2.1]. For infants under six months, use is not fully established [2.1].
• Pregnancy: The medication is not recommended unless necessary for severe or life-threatening infections [3.2]. High-dose and/or prolonged use during the first trimester is associated with a rare pattern of birth defects and is generally avoided [3.5].
• Lactation: A single, low dose is generally considered acceptable; however, use after repeated or high doses is not recommended [3.3].

Alozof Interactions with other medicines and products

Alozof (Fluconazole) has documented interaction patterns that primarily stem from its activity as an inhibitor of specific metabolic enzymes, as outlined in official regulatory documents. This activity necessitates restrictions on co-administration with certain medicinal products.

Contraindicated Combinations

Co-administration with Alozof is formally prohibited for several medicinal products due to the risk of significantly increasing their plasma concentrations, which can lead to severe QT interval prolongation and Torsades de Pointes.

Classification	Examples of Interacting Medicines
Formally Prohibited	Cisapride, Astemizole, Pimozide, Quinidine, Erythromycin, Flibanserin, Lomitapide, Lonafarnib, and Terfenadine (at Alozof doses ge 400 mg/day).

Documented Pharmacokinetic Effects

Alozof is classified as a potent inhibitor of cytochrome P450 CYP2C9 and a moderate inhibitor of CYP3A4 and CYP2C19 enzymes. This inhibition reduces the clearance of numerous co-administered drugs that are substrates of these enzymes, leading to increased systemic exposure.

• Exposure Increase: The area under the curve (AUC) and maximum plasma concentration (C max) of medicines like Warfarin (increased prothrombin time), Midazolam, Cyclosporine, and certain Oral Contraceptives are officially reported to increase.
• Alozof Exposure Modification: Rifampicin significantly decreases Alozof plasma concentration, while Hydrochlorothiazide is documented to increase it by approximately 40%.

Food and Population Notes

The absorption of Alozof is not clinically impaired when taken with food. Official labeling includes cautions for patients with hepatic impairment, and notes that patients with hypokalemia have an increased risk for cardiotoxicity from documented interactions.

Alozof's mechanism is highly selective, focusing exclusively on essential biological systems within the fungal cell, leading to fungal growth inhibition.

---

Blocking the Fungal Sterol Synthesis Pathway

Alozof is a selective inhibitor of the fungal enzyme lanosterol 14-alpha- demethylase ( CYP51), an essential molecular target for building the fungal cell membrane. The drug coordinates with the heme iron of this enzyme, interrupting the metabolic pathway required to create ergosterol, the primary sterol that provides structural integrity and fluidity to the fungal membrane.

---

Disruption of Fungal Cell Membrane Structure and Function

The blockade of ergosterol synthesis triggers a damaging cascade: the cell membrane becomes deficient in its essential stabilizing component while simultaneously accumulating toxic 14-alpha- methylsterols. This corruption of the fungal cell structure leads to severely increased permeability and compromised function, directly causing the organism to be unable to grow, replicate, or survive.

How to Use Alozof: Official Administration Guidelines

Alozof (Fluconazole) is used according to specific, standardized instructions regarding administration route, dosage, frequency, and duration. The dosage is the same for both oral and intravenous administration, with the choice of route depending on the patient's clinical status.

Official Routes of Administration and Key Instructions

Feature	Instruction
Route of Administration	Oral (capsule, tablet, suspension) and Intravenous (IV) by slow infusion.
Timing in Relation to Meals	Oral forms may be taken with or without food.
IV Infusion Rate	Must be administered at a rate not exceeding 10 mL/minute (200 mg/hour).

Standard Dosing Patterns

The regimen for many conditions, particularly systemic infections, often begins with a loading dose on Day 1, which is twice the subsequent once-daily maintenance dose, to ensure therapeutic plasma concentrations are achieved quickly.

• Single-Dose: 150 mg as a single oral dose is used for acute vaginal candidiasis.
• Multiple-Dose Examples: For oropharyngeal candidiasis, a regimen is often 200 mg on Day 1, followed by 100 mg once daily for a minimum of two weeks. For systemic candidiasis, the loading dose is 800 mg, followed by 400 mg once daily.

Special Populations and Duration

Treatment duration is highly dependent on the condition, ranging from a single day to up to six months for prophylaxis of recurrent vaginal candidiasis or indefinitely for preventing relapse of cryptococcal meningitis in certain patient groups.

• Renal Impairment: After the initial loading dose, the subsequent maintenance dose must be reduced by 50% for patients with Creatinine Clearance le 50 mL/min who are not receiving dialysis.
• Pediatric Dosing: Doses for children are typically calculated based on body weight in mg/kg.

Research Evidence / Overview of Studies for Alozof

Alozof (Fluconazole) was evaluated in research that includes comparative trials, randomized controlled studies, and broader analyses. This evidence describes the design of studies that were conducted across its studied indications, focusing on measured outcomes, observed patterns, and areas still requiring further research, according to regulatory and scientific literature.

---

Evidence for Systemic Fungal Infections (Candidemia)

Research here includes Randomized Controlled Trials (RCTs) that research examined Alozof against various comparators. Studies were conducted in diverse groups, including critically ill patients in the Intensive Care Unit (ICU) and adults with systemic fungal infection. Researchers primarily studies monitored outcomes related to systemic or functional imbalance, such as all-cause mortality and the rate of fungal clearance from the bloodstream (microbiological response).

The findings describe patterns observed in the studies that research explored in short-term treatment settings for certain patient groups, especially when the organism is known to be susceptible. Some trials monitored how outcomes evolved in patient groups where the treatment changed from intravenous to oral formulation during the study period.

---

Evidence for Central Nervous System Infections (Cryptococcal Meningitis)

This part describes the structure of the research concerning Alozof's application in both the initial phase and the long-term maintenance phase of cryptococcal meningitis, based on comparative and cohort studies. Clinical trials research examined the use of Alozof in conditions characterized by fluctuating or episodic manifestations, focusing on immunocompromised adults. Key outcomes was evaluated in these settings included the rate of fungal sterilization in the Cerebrospinal Fluid (CSF) and the rate of recurrence in the long-term follow-up phase.

What remains uncertain: Findings were mixed regarding its use as a single agent during the initial, acute phase of the infection. Some studies was observed in some studies to be associated with lower success measurements and resistance. The research describes that other studies focused on combination therapy.

---

Research Gaps and Areas of Uncertainty

This concluding section synthesizes the main evidence limitations and areas where official sources note uncertainty. There is limited information for long-term outcomes regarding the recurrence of many fungal conditions following treatment, with the exception of specific, high-risk populations. Ongoing research is ongoing to monitor the possibility that widespread use may be associated with changes in fungal colonization patterns or the development of resistance. Additionally, subgroup findings are uncertain or insufficient for certain highly specific patient groups, meaning the results apply only to the populations studied within the major trials.

Key Studies & References

1. Dutch Medicines Evaluation Board (CBG-MEB) Public Assessment Report for Fluconazole
2. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America (IDSA)
3. Cryptococcosis: Adult and Adolescent Opportunistic Infections Guidelines (NIH/Clinicalinfo)

Common questions about Alozof (FAQ)

---

Q: Is it safe to drink alcohol while on this medication?

Official regulatory labels generally do not prohibit the use of alcohol with this medicine. However, the official product information does note a risk of hepatotoxicity (liver damage) associated with Alozof use. Patients who consume alcohol may wish to discuss their liver health with a healthcare professional.

---

Q: If I have kidney problems, how do I adjust my daily dose?

Official dosing guidelines indicate that for patients with significantly reduced kidney function, specifically a Creatinine Clearance of 50 mL/min or less, the maintenance dose is typically adjusted. Following the initial starting dose, the daily maintenance dose is typically reduced for these patients.

---

Q: Can this drug be used in patients with severe liver disease?

Regulatory documents advise caution when giving Alozof to patients who have existing liver problems, as the drug carries a risk of liver toxicity. Though this can range from mild effects to, rarely, severe hepatic failure, official guidelines note that the drug may need to be discontinued if signs of liver dysfunction appear.

---

Q: How does Rifampicin interact with Alozof?

According to official drug interaction information, taking Alozof with Rifampicin significantly decreases the level of Alozof in the bloodstream. This occurs because Rifampicin speeds up the body's natural processes (enzyme induction) that break down Alozof, which may lead to lower drug exposure in the body.

---

Q: Is there a risk of becoming addicted to Alozof?

Official regulatory documents and safety data sheets for Alozof do not include any warnings or specific information related to the potential for abuse, physical dependence, or addiction.

---

Q: What should I do if I miss a scheduled dose?

Official guidance suggests that if a regular dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next dose, it is suggested that the missed dose be skipped, and the regular schedule resumed. Official patient leaflets include a caution against taking an increased dose to make up for a skipped dose.

How to Store and Dispose of Alozof

Storage requirements for Alozof (Fluconazole) must adhere to official regulatory specifications, which vary by dosage form to maintain stability.

Storage Conditions

Oral tablets and capsules must be stored below 30 C (86 F), protected from moisture, and kept in the original container, tightly closed. The intravenous solution and the reconstituted oral suspension must be protected from freezing. The mixed oral suspension has a limited shelf-life and must be discarded after 14 days, even if properly stored.

Handling and Disposal

Keep Alozof out of the sight and reach of children. Unused or expired medication should not be disposed of in the wastewater. Disposal should follow official guidelines, preferably through a local drug take-back program. If a program is unavailable, follow the sanctioned household disposal steps provided by the FDA, which involve mixing the product with an undesirable substance and sealing it.